Purpose
Neoadjuvant therapy modality can increase the operability rate and mitigate pathological risks in locally advanced cervical cancer, but treatment response varies widely. It remains unclear whether genetic alterations correlate with the response to neoadjuvant therapy and disease-free survival (DFS) in locally advanced cervical cancer.
Materials and Methods
A total of 62 locally advanced cervical cancer (stage IB-IIA) patients who received neoadjuvant chemoradiation plus radical hysterectomy were retrospectively analyzed. Patients’ tumor biopsy samples were comprehensively profiled using targeted next generation sequencing. Pathologic response to neoadjuvant treatment and DFS were evaluated against the association with genomic traits.
Results
Genetic alterations of PIK3CA were most frequent (37%), comparable to that of Caucasian populations from The Cancer Genome Atlas. The mutation frequency of genes including TERT, POLD1, NOS2, and FGFR3 was significantly higher in Chinese patients whereas RPTOR, EGFR, and TP53 were underrepresented in comparison to Caucasians. Germline mutations were identified in 21% (13/62) of the cohort and more than half (57%) had mutations in DNA damage repair genes, including BRCA1/2, TP53 and PALB2. Importantly, high tumor mutation burden, TP53 polymorphism (rs1042522), and KEAP1 mutations were found to be associated with poor pathologic response to neoadjuvant chemoradiation treatment. KEAP1 mutations, PIK3CA-SOX2 co-amplification, TERC copy number gain, and TYMS polymorphism correlated with an increased risk of disease relapse.
Conclusion
We report the genomic profile of locally advanced cervical cancer patients and the distinction between Asian and Caucasian cohorts. Our findings highlight genomic traits associated with unfavorable neoadjuvant chemoradiation response and a higher risk of early disease recurrence.
Citations
Citations to this article as recorded by
Cytokine Gene Variants as Risk Predictors and Prognostic Biomarkers for Cervix Cancer: A Revisit Atar Singh Kushwah, Maneesh Kumar Gupta, Kirti Srivastava, Monisha Banerjee Current Cancer Therapy Reviews.2026; 22(3): 234. CrossRef
Distinct Molecular and Prognostic Profiles of Left‐ and Right‐Sided Colorectal Cancer Revealed by NGS Analysis: The Role of SMAD4 and SETD2 Mutations Wenlei Zhao, Yuxuan Qiu, Na Bai, Chunhong He, Jiani C. Yin, Qianru Xu, Kaiyu Jian, Baolei Jia, Lin Jiang, Feng Liang Cancer Medicine.2026;[Epub] CrossRef
Enriched NKX2-1 Mutations in Bronchiolar Adenoma Variants: Evidence for Malignant Transformation or an Indolent Entity Lu-yao Li, Gong-ming Dong, Yi-xin Ma, Jie Liu, Yan Shi, Fu-quan Jia, Guan-jun Zhang Current Medical Science.2026; 46(1): 116. CrossRef
PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability Alessandro Ottaiano, Carmine Picone, Mariachiara Santorsola, Massimiliano Berretta, Carmen Cutolo, Andrea Belli, Francesco Izzo, Nadia Di Carluccio, Aniello Acampora, Luca Tarotto, Salvatore Stilo, Marco Correra, Maurizio Capuozzo, Anna Chiara Carratù, Mi Cancers.2026; 18(17): 2798. CrossRef
BRCA1 Mutations and Their Consequences in Multiple Cancers: Molecular Insights and Emerging Therapeutic Strategies Swaroop Kumar Pandey, Swarnima Paliwal, Braj Bhushan Mall Current Cancer Therapy Reviews.2026; 22(5): 521. CrossRef
Predictive role of ARID1A and B2M mutations and the antigen presentation pathway in the efficacy of definitive chemoradiotherapy for cervical cancer Chenjing Zhu, Zhen Gong, Ping Yin, Jian Huang, Dan He, Biqing Zhu, Yaqin Wu, Hairong Wang, Yaru Zhang, Qifan Jing, Jiani C Yin, Yue Li, Jianyao Liu, Huanhuan Hu, Shuyue Xiao, Zhihua Sun, Hanzi Xu The Oncologist.2025;[Epub] CrossRef
A Comparative Analysis of Usual- and Gastric-Type Cervical Adenocarcinoma in a Japanese Population Reveals Distinct Clinicopathological and Molecular Features with Prognostic and Therapeutic Insights Umme Farzana Zahan, Hasibul Islam Sohel, Kentaro Nakayama, Masako Ishikawa, Mamiko Nagase, Sultana Razia, Kosuke Kanno, Hitomi Yamashita, Shahataj Begum Sonia, Satoru Kyo International Journal of Molecular Sciences.2025; 26(15): 7469. CrossRef
Comprehensive characterization of PKHD1 mutation in human colon cancer Lu Han, Fangming Gong, Xuxiaochen Wu, Wanxiangfu Tang, Hua Bao, Yue Wang, Daizhenru Wang, Yulan Sun, Peng Li Cancer Medicine.2024;[Epub] CrossRef
PBRM1 presents a potential ctDNA marker to monitor response to neoadjuvant chemotherapy in cervical cancer Wenhan Li, Yuhui Huang, Man Xiao, Jing Zhao, Shi Du, Zehua Wang, Sha Hu, Lu Yang, Jing Cai iScience.2024; 27(3): 109160. CrossRef
Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real‐world cohort analysis Yi Sun, Shilei Qin, Song Wang, Jiaohui Pang, Qiuxiang Ou, Weiquan Liang, Hai Zhong The Journal of Pathology: Clinical Research.2024;[Epub] CrossRef
PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer Cong Wang, Lijun Liu, Xia Li, Jia Lei, Yiqian Li, Zhibo Shen, Huirong Shi, Yan Cheng Future Oncology.2024; 20(20): 1415. CrossRef
A biomarker exploration in small-cell lung cancer for brain metastases risk and prophylactic cranial irradiation therapy efficacy Li Li, Ning Liu, Tao Zhou, Xueting Qin, Xiaoyu Song, Song Wang, Jiaohui Pang, Qiuxiang Ou, Yong Wang, Dexian Zhang, Jiaran Li, Fuhao Xu, Shuming Shi, Jinming Yu, Shuanghu Yuan Lung Cancer.2024; 196: 107959. CrossRef
Prospects of POLD1 in Human Cancers: A Review Michał Gola, Przemysław Stefaniak, Janusz Godlewski, Barbara Jereczek-Fossa, Anna Starzyńska Cancers.2023; 15(6): 1905. CrossRef
Copy-number-gain of telomerase reverse transcriptase (hTERT) is associated with an unfavorable prognosis in esophageal adenocarcinoma Su Ir Lyu, Felix C. Popp, Adrian Georg Simon, Anne Maria Schultheis, Thomas Zander, Caroline Fretter, Wolfgang Schröder, Christiane J. Bruns, Thomas Schmidt, Alexander Quaas, Karl Knipper Scientific Reports.2023;[Epub] CrossRef